GP2

By Targets:	Bacterial (2) Cannabinoid Receptor (1) Cytochrome P450 (6) EGFR (1) Endogenous Metabolite (7) HIV (6) HIV Protease (6) Isotope-Labeled Compounds (3) P-glycoprotein (6) SARS-CoV (6) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (8) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective *CB2* cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-RS05609

GP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GP2 Human Pre-designed siRNA Set A contains three designed siRNAs for GP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GP2 Human Pre-designed siRNA Set A GP2 Human Pre-designed siRNA Set A

HY-U00191

GP2-114

Others Cardiovascular Disease

GP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.

GP2-114	Others	Cardiovascular Disease
GP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.

HY-P5695

GP-2B	Bacterial	Infection
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-147089

PRRSV/CD163-IN-1	Bacterial Endogenous Metabolite	Infection Inflammation/Immunology
PRRSV/CD163-IN-1 is a PRRSV/CD163 inhibitor. PRRSV/CD163-IN-1 can inhibit the interaction between the PRRSV glycoprotein (GP2a or GP4) and the CD163-SRCR5 domain. PRRSV/CD163-IN-1 can be used for the research of porcine reproductive and respiratory syndrome (PRRS) .

HY-17367S3

Atazanavir-d5	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9 BMS-232632-d₉	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S4

Atazanavir-d6 BMS-232632-d₆	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367R

Atazanavir (Standard)	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

Cat. No.	Product Name	Target	Research Area

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P5695

GP-2B	Bacterial	Infection
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-147089

PRRSV/CD163-IN-1	Infection Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Bacterial Endogenous Metabolite
PRRSV/CD163-IN-1 is a PRRSV/CD163 inhibitor. PRRSV/CD163-IN-1 can inhibit the interaction between the PRRSV glycoprotein (GP2a or GP4) and the CD163-SRCR5 domain. PRRSV/CD163-IN-1 can be used for the research of porcine reproductive and respiratory syndrome (PRRS) .

HY-P5695

GP-2B	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Bacterial
GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .

HY-17367R

Atazanavir (Standard)	Structural Classification Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

Species:	Human (1) Virus (2)
Tag:	His (2) Fc (1)
Source:	HEK293 (1) E. coli Cell-free (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71814

	PODXL Protein, Human (P.pastoris, His) GCTM-2 antigen; GP2; GP200; PCLP1; Pcx; Podocalyxin; Podocalyxin like; Podocalyxin like protein; Podocalyxin-like protein 1; Podxl	Human	P. pastoris
	PODXL proteins coordinate multiple cellular functions, acting as anti-adhesion and pro-adhesion molecules. In podocytes, it maintains open filtration pathways through charge repulsion and promotes migration and cell-cell contacts in an integrin-dependent manner. PODXL Protein, Human (P.pastoris, His) is the recombinant human-derived PODXL protein, expressed by P. pastoris , with N-His labeled tag.

HY-P702299

	GP2b Protein, PRRSV (Cell-Free, His) Envelope small membrane protein; Glycoprotein 2b; Protein GP2b; Gs	Virus	E. coli Cell-free
	GP2b Protein, a minor envelope protein, potentially acts as a viroporin, aiding virus uncoating for genomic RNA release into the cytoplasm. It forms homooligomers, creating higher-order structures like dimers, trimers, and tetramers. GP2b is likely part of the GP2a-GP3-GP4 complex, contributing to the overall functionality of the viral envelope. GP2b Protein, PRRSV (Cell-Free, His) is the recombinant Virus-derived GP2b protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of GP2b Protein, PRRSV (Cell-Free, His) is 69 a.a., with molecular weight of 13.7 kDa.

HY-P76890

	*Ebola virus Glycoprotein/GP2* Protein (AHX24649, HEK293, Fc)** Ebola virus EBOV (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) GP2 / Glycoprotein Protein (Fc)	Virus	HEK293
	Ebola virus glycoproteins (GPs) play a key role in the virus entry process, with GP1 serving as the receptor-binding subunit and GP2 for membrane fusion. GP downregulates host cell surface molecules, disrupts adhesion and may lead to disruption of vascular integrity. Ebola virus Glycoprotein/GP2 Protein (AHX24649, HEK293, Fc) is the recombinant Virus-derived Ebola virus Glycoprotein/GP2 protein, expressed by HEK293 , with N-mFc labeled tag. The total length of Ebola virus Glycoprotein/GP2 Protein (AHX24649, HEK293, Fc) is 149 a.a., with molecular weight of ~43.4 KDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82094

Integrin alpha IIb Antibody (YA1839)

ITGA2B; GP2B; ITGAB; Integrin alpha-IIb; GPalpha IIb; GPIIb; Platelet membrane glycoprotein IIb; CD41
WB Human, Rat

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

GP2

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products